Successful Treatment with Osimertinib Based on Therapeutic Drug Monitoring in a Hemodialysis Patient with Non-Small Cell Lung Cancer: A Case Report

Successful Treatment with Osimertinib Based on Therapeutic Drug Monitoring in a Hemodialysis Patient with Non-Small Cell Lung Cancer: A Case Report

Although osimertinib is a key drug in the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation, the safety in hemodialysis patients has not been established. A 76-year-old man was diagnosed with NSCLC with EGFR deletion mutation in exon 19. After trea...

Full description

Bibliographic Details
Main Authors: Keisuke Tabata, Masaya Aoki, Ryo Miyata, Tadashi Umehara, Aya Harada-Takeda, Go Kamimura, Toshiyuki Nagata, Ryuya Okizono, Hideyuki Terazono, Yasuo Takeda, Takayuki Suetsugu, Kazuhiro Ueda, Masami Sato
Format: Article
Language:English
Published: Karger Publishers 2023-08-01
Series:Case Reports in Oncology
Subjects:
epidermal growth factor receptor mutation
osimertinib
plasma concentration
hemodialysis
case report
Online Access:https://beta.karger.com/Article/FullText/531840

Internet

https://beta.karger.com/Article/FullText/531840

Similar Items